@article{Creuzot_Garcher2023-bx,

title = {Management of neovascular age-related macular degeneration 

 treatment in France from 2008-2018: The nationwide LANDSCAPE 

 study},

author = {Catherine P Creuzot Garcher and Mayer Srour and Florian Baudin and Corinne Dot and Sylvia Nghiem-Buffet and Jean-Francois Girmens and Cedric Collin and Anne Ponthieux and Cécile Delcourt},

year  = {2023},

date = {2023-10-01},

journal = {Ophthalmol. Ther.},

volume = {12},

number = {5},

pages = {2687–2701},

abstract = {INTRODUCTION: The aim of this study was to describe the 

 management of neovascular age-related macular degeneration (nAMD) 

 in French patients between 2008 and 2018. METHODS: This was a 

 retrospective longitudinal cohort study using exhaustive 

 nationwide health records from the French National Health 

 Information database. Enrollment criteria were adults aged $geq$ 

 50 years, nAMD diagnosis, or reimbursement for nAMD treatments 

 (anti-vascular epithelial growth factor [VEGF] injection or 

 dynamic phototherapy with verteporfin). Exclusion criteria were 

 high myopia, diagnosis of other retinal diseases, and treatments 

 for other macular diseases (dexamethasone implant, laser). Main 

 outcome measures were consumption of medical care and nAMD 

 treatments per calendar year and number of years of follow-up. 

 RESULTS: Between 2008 and 2018, we identified 342,961 patients 

 who have been treated for nAMD. Median duration of 

 ophthalmological follow-up exceeded 7 years (90 months). The 

 median annual number of ophthalmology consultations decreased 

 from nine visits in year 1 after treatment initiation to four 

 visits from year 7 onwards. The median duration of nAMD treatment 

 was 10.1 months for all patients, with 48.5% of patients 

 undergoing treatment for < 1 year. Only 24.4% of patients had 

 maintained treatment at year 11. Patients remaining under 

 treatment had a median of four anti-VEGF treatments per year 

 throughout the 10-year study period. Ranibizumab was the more 

 common first-line treatment (67.5% of patients) compared to 

 aflibercept (32.4%). About 20% of patients who initiated 

 treatment switched treatment at least once. CONCLUSIONS: 

 LANDSCAPE provides exhaustive nationwide data on the real-world 

 management of nAMD in France over a 10-year period. Further 

 investigation into short treatment duration is required, 

 especially in terms of understanding its relation to visual 

 outcomes.},

keywords = {Anti-VEGF; Neovascular age-related macular degeneration;   Real-world management; Syst{è}me National des Donn{é}es de   Sant{é}},

pubstate = {published},

tppubtype = {article}

}